191 related articles for article (PubMed ID: 28279154)
1. Receiver operating characteristic analysis of prediction for gastric cancer development using serum pepsinogen and Helicobacter pylori antibody tests.
Hamashima C; Sasazuki S; Inoue M; Tsugane S;
BMC Cancer; 2017 Mar; 17(1):183. PubMed ID: 28279154
[TBL] [Abstract][Full Text] [Related]
2. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
Yoshida T; Kato J; Inoue I; Yoshimura N; Deguchi H; Mukoubayashi C; Oka M; Watanabe M; Enomoto S; Niwa T; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Takeshita T; Ushijima T; Ichinose M
Int J Cancer; 2014 Mar; 134(6):1445-57. PubMed ID: 24009139
[TBL] [Abstract][Full Text] [Related]
3. Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels.
Kishikawa H; Kimura K; Ito A; Arahata K; Takarabe S; Kaida S; Miyauchi J; Miura S; Kanai T; Nishida J
Digestion; 2017; 95(3):229-236. PubMed ID: 28355604
[TBL] [Abstract][Full Text] [Related]
4. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels.
Yanaoka K; Oka M; Yoshimura N; Mukoubayashi C; Enomoto S; Iguchi M; Magari H; Utsunomiya H; Tamai H; Arii K; Yamamichi N; Fujishiro M; Takeshita T; Mohara O; Ichinose M
Int J Cancer; 2008 Aug; 123(4):917-26. PubMed ID: 18508314
[TBL] [Abstract][Full Text] [Related]
5. Serum pepsinogen levels and their influencing factors: a population-based study in 6990 Chinese from North China.
Sun LP; Gong YH; Wang L; Yuan Y
World J Gastroenterol; 2007 Dec; 13(48):6562-7. PubMed ID: 18161928
[TBL] [Abstract][Full Text] [Related]
6. Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis.
Watanabe M; Kato J; Inoue I; Yoshimura N; Yoshida T; Mukoubayashi C; Deguchi H; Enomoto S; Ueda K; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Tekeshita T; Mohara O; Ushijima T; Ichinose M
Int J Cancer; 2012 Dec; 131(11):2632-42. PubMed ID: 22383377
[TBL] [Abstract][Full Text] [Related]
7. Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community.
Zhang X; Xue L; Xing L; Wang J; Cui J; Mi J; Xing X; Wang J; Du Z; Misumi J; Tian Q; Wang L
Int J Cancer; 2012 Apr; 130(7):1614-9. PubMed ID: 21547904
[TBL] [Abstract][Full Text] [Related]
8. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study.
Sasazuki S; Inoue M; Iwasaki M; Otani T; Yamamoto S; Ikeda S; Hanaoka T; Tsugane S;
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1341-7. PubMed ID: 16835334
[TBL] [Abstract][Full Text] [Related]
9. Helicobacter pylori infection and markers of gastric cancer risk in Alaska Native persons: a retrospective case-control study.
Keck JW; Miernyk KM; Bulkow LR; Kelly JJ; McMahon BJ; Sacco F; Hennessy TW; Bruce MG
Can J Gastroenterol Hepatol; 2014 Jun; 28(6):305-10. PubMed ID: 24945184
[TBL] [Abstract][Full Text] [Related]
10. Serum pepsinogen levels indicate the requirement of upper gastrointestinal endoscopy among Group A subjects of ABC classification: a multicenter study.
Chinda D; Shimoyama T; Mikami T; Arai T; Chiba D; Sasaki Y; Komai K; Sawada Y; Saito Y; Chiba H; Fukuda S;
J Gastroenterol; 2018 Aug; 53(8):924-931. PubMed ID: 29353347
[TBL] [Abstract][Full Text] [Related]
11. Predominant mucosal IL-8 mRNA expression in non-cagA Thais is risk for gastric cancer.
Yamada S; Kato S; Matsuhisa T; Makonkawkeyoon L; Yoshida M; Chakrabandhu T; Lertprasertsuk N; Suttharat P; Chakrabandhu B; Nishiumi S; Chongraksut W; Azuma T
World J Gastroenterol; 2013 May; 19(19):2941-9. PubMed ID: 23704827
[TBL] [Abstract][Full Text] [Related]
12. Serum pepsinogen values and Helicobacter pylori status among control subjects of a nested case-control study in the JACC study.
Kikuchi S; Yagyu K; Obata Y; Yingsong L; Yatsuya H; Hoshiyama Y; Kondo T; Sakata K; Mizoue T; Tokui N; Fujino Y; Tamakoshi A; Toyoshima H; Ishibashi T; Hayakawa N; Yoshimura T;
J Epidemiol; 2005 Jun; 15 Suppl 2(Suppl II):S126-33. PubMed ID: 16127224
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of serum markers for gastric cancer and its precursor diseases among high incidence and mortality rate of gastric cancer area.
Gantuya B; Oyuntsetseg K; Bolor D; Erdene-Ochir Y; Sanduijav R; Davaadorj D; Tserentogtokh T; Uchida T; Yamaoka Y
Gastric Cancer; 2019 Jan; 22(1):104-112. PubMed ID: 29934751
[TBL] [Abstract][Full Text] [Related]
14. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis.
Terasawa T; Nishida H; Kato K; Miyashiro I; Yoshikawa T; Takaku R; Hamashima C
PLoS One; 2014; 9(10):e109783. PubMed ID: 25314140
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic Value of Serum Pepsinogen Ⅰ/Pepsinogen Ⅱ Combined with Tumor Markers for
Wang SS; Guo ZP; Zhao XY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 54(1):186-191. PubMed ID: 36647665
[TBL] [Abstract][Full Text] [Related]
16. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm.
Choi HS; Lee SY; Kim JH; Sung IK; Park HS; Shim CS; Jin CJ
J Dig Dis; 2014 Jun; 15(6):293-8. PubMed ID: 24602176
[TBL] [Abstract][Full Text] [Related]
17. Optimal Criteria and Diagnostic Ability of Serum Pepsinogen Values for Helicobacter pylori Infection.
Kikuchi S; Kato M; Mabe K; Kawai T; Furuta T; Inoue K; Ito M; Yoshihara M; Kodama M; Murakami K
J Epidemiol; 2019 Apr; 29(4):147-154. PubMed ID: 30249942
[TBL] [Abstract][Full Text] [Related]
18. Identification of a high risk gastric cancer group using serum pepsinogen after successful eradication of Helicobacter pylori.
Haneda M; Kato M; Ishigaki S; Suzuki M; Takahashi M; Nakagawa M; Ono S; Mori Y; Mabe K; Nakagawa S; Kudo T; Shimizu Y; Asaka M
J Gastroenterol Hepatol; 2013 Jan; 28(1):78-83. PubMed ID: 23034090
[TBL] [Abstract][Full Text] [Related]
19. Serum pepsinogens, gastrin-17 and Helicobacter pylori antibody in the residents of two cities in china with distinct mortality rates of gastric cancer.
Zheng KC; Aoki K; Li XQ; Lin SG; Wu BS; Zhong WL; Chen TH; Lin S; You JW; Su C
Tohoku J Exp Med; 2012 Dec; 228(4):289-94. PubMed ID: 23117263
[TBL] [Abstract][Full Text] [Related]
20. Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: analysis of 5732 Japanese subjects.
Yamaji Y; Mitsushima T; Ikuma H; Okamoto M; Yoshida H; Kawabe T; Shiratori Y; Saito K; Yokouchi K; Omata M
Gut; 2001 Sep; 49(3):335-40. PubMed ID: 11511553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
